# Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

> **NCT02994056** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 32 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02994056
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-23
- **Primary completion:** 2018-09-25
- **Final completion:** 2018-12-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02994056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02994056, "Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02994056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*